Sign In
Buy DYAI
Dyadic International Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.0500 |
| EPS Surprise | -25.00% |
| Revenue estimate | 903.75K |
| Revenue actual | 1.111M |
| Revenue Surprise | 22.93% |
| Release date | Mar 25, 2026 |
| EPS estimate | -$0.0300 |
| EPS actual | -$0.0600 |
| EPS Surprise | -100.00% |
| Revenue estimate | 1.343M |
| Revenue actual | 564.345K |
| Revenue Surprise | -57.99% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.0600 |
| EPS Surprise | -50.00% |
| Revenue estimate | 1.343M |
| Revenue actual | 1.165M |
| Revenue Surprise | -13.30% |
| Release date | Aug 13, 2025 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.0600 |
| Revenue estimate | 1.5M |
| Revenue actual | 463.449K |
| Revenue Surprise | -69.10% |
Last 4 Quarters for Dyadic International
Below you can see how DYAI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2025 |
| Price on release | $0.82 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.0600 |
| Date | Price |
|---|---|
| Aug 07, 2025 | $0.95 |
| Aug 08, 2025 | $0.94 |
| Aug 11, 2025 | $0.81 |
| Aug 12, 2025 | $0.85 |
| Aug 13, 2025 | $0.82 |
| Aug 14, 2025 | $0.80 |
| Aug 15, 2025 | $0.748 |
| Aug 18, 2025 | $0.795 |
| Aug 19, 2025 | $0.790 |
| 4 days before | -13.68% |
| 4 days after | -3.63% |
| On release day | -2.44% |
| Change in period | -16.81% |
| Release date | Nov 12, 2025 |
| Price on release | $0.94 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.0600 |
| EPS surprise | -50.00% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $0.98 |
| Nov 07, 2025 | $0.93 |
| Nov 10, 2025 | $1.00 |
| Nov 11, 2025 | $0.98 |
| Nov 12, 2025 | $0.94 |
| Nov 13, 2025 | $0.91 |
| Nov 14, 2025 | $0.91 |
| Nov 17, 2025 | $0.89 |
| Nov 18, 2025 | $0.90 |
| 4 days before | -3.94% |
| 4 days after | -4.19% |
| On release day | -3.87% |
| Change in period | -7.96% |
| Release date | Mar 25, 2026 |
| Price on release | $0.87 |
| EPS estimate | -$0.0300 |
| EPS actual | -$0.0600 |
| EPS surprise | -100.00% |
| Date | Price |
|---|---|
| Mar 19, 2026 | $0.798 |
| Mar 20, 2026 | $0.94 |
| Mar 23, 2026 | $0.86 |
| Mar 24, 2026 | $0.84 |
| Mar 25, 2026 | $0.87 |
| Mar 26, 2026 | $0.701 |
| Mar 27, 2026 | $0.679 |
| Mar 30, 2026 | $0.730 |
| Mar 31, 2026 | $0.82 |
| 4 days before | 9.29% |
| 4 days after | -6.02% |
| On release day | -19.63% |
| Change in period | 2.72% |
| Release date | May 13, 2026 |
| Price on release | $0.711 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.0500 |
| EPS surprise | -25.00% |
| Date | Price |
|---|---|
| May 07, 2026 | $0.745 |
| May 08, 2026 | $0.767 |
| May 11, 2026 | $0.724 |
| May 12, 2026 | $0.723 |
| May 13, 2026 | $0.711 |
| May 14, 2026 | $0.690 |
| May 15, 2026 | $0.722 |
| May 18, 2026 | $0.720 |
| May 19, 2026 | $0.721 |
| 4 days before | -4.63% |
| 4 days after | 1.48% |
| On release day | -2.89% |
| Change in period | -3.22% |
Dyadic International Earnings Call Transcript Summary of Q1 2026
Dyadic is transitioning from a platform R&D company to a commercially focused biotech with multiple near-term revenue paths. Q1 2026 revenue was $1.1M (up 182% YoY) driven by R&D/grant revenue and milestones; cost of revenue rose with program activity. Net loss improved slightly to $1.95M ($0.05/sh). Cash and equivalents were $6.6M at March 31, 2026, and management expects cash runway into Q2 2027 assuming similar or lower FY2026 burn (last year < $5.7M). Key commercial developments: Proliant’s commercial launch of Albufree Dx (Dyadic eligible for profit share); commercial launches/shipments of DNase‑1 (with Fermbox and IBT distribution) and recombinant bovine transferrin (initial orders, IBT OEM distribution); Inzymes’ commercialized recombinant bovine chymosin and BRIG BIO collaboration for alpha‑lactalbumin (customer sampling expected mid‑2026). Biopharma work remains partner‑driven (Gates Foundation, CEPI via Fondazione Biotecnopolo di Siena) validating the C1 platform for antibodies and vaccine antigens and generating non‑dilutive funding (~$3M Gates; up to ~$2.4M CEPI). Strategy emphasizes leveraging C1 and Dapibus platforms to produce scalable, animal‑free proteins/enzymes across life sciences, food & nutrition, and bioindustrial markets via partnerships, OEM distribution, and manufacturing partners (Fermbox) while managing expenses. Management expects product revenue growth in 2026 from Life Sciences and Food & Nutrition channels, milestone and royalty potential from partners, and selective hiring/outsourced commercial expansion tied to revenue growth.
